Voyager Therapeutics Inc. (NASDAQ:VYGR) traded down 1.8% during mid-day trading on Thursday . The stock traded as low as $15.84 and last traded at $15.97, with a volume of 53,766 shares trading hands. The stock had previously closed at $16.26.

A number of research firms have weighed in on VYGR. Piper Jaffray Cos. restated a “buy” rating on shares of Voyager Therapeutics in a research report on Saturday, April 30th. Zacks Investment Research downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 26th. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Cowen and Company restated a “buy” rating on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Finally, Wells Fargo & Co. began coverage on Voyager Therapeutics in a research report on Friday, May 20th. They set an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $30.25.

The company has a 50-day moving average of $13.76 and a 200-day moving average of $11.89. The company’s market cap is $426.85 million.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.03. Analysts expect that Voyager Therapeutics Inc. will post ($1.49) EPS for the current year.

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.